NON-CME WEBINAR

THE

NEW 4-WEEKS
DOSING OPTION

FOR PEGUNIGALSIDASE ALFA:
CLINICAL EVIDENCE AND PRATICAL CONSIDERATIONS

Register now / Login now Download Program (PDF)

Program

1. SmPC changes and key updates
Speaker: Prof. A. Linhart

2. Practical considerations from the SmPC
Speaker: Prof. A. Linhart

3. BRIGHT and F51 studies: evidence on E4W dosing
Speaker: Prof. A. Linhart

4. Practical management of patients treated with pegunigalsidase alfa
Speaker: Dr. G. Dostálová

Faculty

Aleš Linhart · Gabriela Dostálová
Charles University and General University Hospital, Prague

Access the Webinar

Available online from October 1, 2026 to September 30, 2027. Register at e-learning-fabry.com.

For information:
alessandro.capasso@fclassevents.com

This webinar is intended exclusively for healthcare professionals practicing in countries where the every-4-weeks (E4W) dosing regimen for pegunigalsidase alfa has been approved.

This webinar is sponsored by
Chiesi Farmaceutici S.p.A.

First Class – Meetings and Conferences
Via Vittoria Colonna, 40 20149 Milano Italy
Tel. +39 02 30066329

ALL_26_1421 · Prepared in July 2026 · Available online Oct 1, 2026 – Sep 30, 2027

Scroll to top

This webinar is intended exclusively for healthcare professionals practicing in countries where the every-4-weeks (E4W) dosing regimen for pegunigalsidase alfa has been approved

By clicking "OK", I declare that I am a healthcare professional practicing in a country where the every-4-weeks (E4W) dosing regimen for pegunigalsidase alfa is approved and that I am eligible to access the content of this webinar.

Ok